Opening Remarks: Daniela Bota, MD, PhD

8:00 - 8:05 AM

Session 1: COVID-19 Clinical Trials

Moderated by Daniela Bota, MD, PhD

John Zaia, MD
Antibody Use for Treatment or Prevention of COVID-19

8:10 - 8:25 AM

Michael Matthay, MD
Cellular Therapy for Acute Respiratory Failure - Mesenchymal Stromal Cells

8:25 - 8:40 AM

Leonid Groysman, MD
United We Stand

8:40 - 8:50 AM

Albert Wong, MD
Identifying the Peptides that Activate T Cells in COVID-19 Patients

8:50 - 9:05 AM

Panel Discussion

9:05 - 9:15 AM

Session 2: Neurodegenerative Diseases
(Alzheimer's, etc.)

Moderated by Clive Svendsen, PhD

HD CARE (Patient advocacy group)

9:25 - 9:40 AM

Ralph Kern, MD, MHSc
NurOwn® (Autologous MSC-NTF Cells) in ALS-Phase 3 Clinical Trial Update

9:40 - 9:55 AM

Jeanne Loring, PhD
Neuron Replacement Therapy for Parkinson’s Disease

9:55 - 10:10 AM

Leslie Thompson, PhD
Stem Cell Based Therapy for Huntington’s Disease

10:10 - 10:25 AM

Panel Discussion

10:25 - 10:40 AM

Session 3: Eye Diseases

Moderated by Dennis Clegg, PhD

Kristin MacDonald - Patient advocate

10:55 - 11:10 AM

Henry Klassen, MD, PhD
Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa

11:10 - 11:25 AM

Theodore Leng, MD, FACS
NeuBright, a Purified Allogeneic Cell Therapy Product for Treatment of Dry Age-related Macular Degeneration

11:25 - 11:40 AM

Sophie Deng, MD, PhD
Limbal Stem Cell Therapy

11:40 - 11:55 AM

Panel Discussion

11:55 - 12:10 PM

Session 4: Blood and Immune System Disorders

Moderated by Crystal Mackall, MD

Alysia Vaccaro - Patient advocate

1:05 - 1:20 PM

Jennifer Puck, MD
Gene Therapy for Artemis Severe Combined Immunodeficiency (ART-SCID)

1:20 - 1:35 PM

Don Kohn, MA, PhD
Hematopoietic Stem Cell Gene Therapy for Primary Immune Deficiencies

1:35 - 1:50 PM

Mark Walters, MD
Gene Correction in Sickle Cell Disease

1:50 - 2:05 PM

Panel Discussion

2:05 - 2:20 PM

Session 5: Cardiac Stem Cells

Moderated by Anthony DeMaria, MD

Pat Farrant - Patient advocate

2:35 - 2:50 PM

Deepak Srivastava, MD
Cellular Reprogramming Approaches for Heart Disease

2:50 - 3:05 PM

Mark Mercola, PhD
Induced Pluripotent Stem Cell (iPSC)-derived Cardiomyocytes for Predicting and Removing Drug Cardiotoxicity

3:05 - 3:20 PM

Debora Lieu, PhD
The Quest for Pacemaking Cardiomyocytes to Engineer Biopacemakers

3:20 - 3:35 PM

Panel Discussion

3:35 - 3:50 PM

Session 6: Knowledge Network

Moderated by Keith Yamamoto, PhD

Experts sharing perspectives on institutional, state and national efforts to create knowledge networks that accelerate benchtop research, clinical trials, and patient access to experimental and approved therapies. A discussion of how best to capture and integrate various datasets to improve understanding of diseases, discovery of novel targets, therapeutic candidates and biomarkers, accelerating clinical development and approval of novel therapies and enhancing patient access and affordability.

4:00-6:00 PM

Sergio Baranzini, PhD
Distinguished Professor of Neurology, UC San Francisco
Member, International MS Genetics Consortium

Susan Gregurick, PhD
Associate Director for Data Science
National Institutes of Health

Oluwadamilola "Lola" Fayanju, MD
Assistant Professor of Surgery
Assistant Professor in Population Health Sciences
Associate Director for Disparities & Value in Healthcare with Duke Forge
Director, Durham VA Breast Clinic

Robert Califf, MD
Donald F. Fortin, M.D. Distinguished Professor of Cardiology,
Member, Duke Clinical Research Institute
Former Commissioner, US Food and Drug Administration

David Haussler, PhD
Investigator, Howard Hughes Medical Institute
Distinguished Professor, Biomolecular Engineering
Scientific Director, UC Santa Cruz Genomics Institute
Former Team Leader, International Human Genome Project